SIG-002
Pre-clinical- Indications
- Type 1 diabetes
Company intelligence / Profile preview
Sigilon Therapeutics
Cambridge, Massachusetts, United Stateslilly.com ↗
- Ownership
- Private
- Employees
- ~62
- Development stage
- Preclinical
01
Overview
Sigilon's lead product candidate SIG-002 is designed to replace islet cells for the treatment of Type 1 Diabetes. The company is developing cell-based therapies that are protected from immune rejection using their proprietary Afibromer™ biomaterials matrix.
- Therapeutic areas
- EndocrinologyImmunologyRare DiseasesHematologyOther
- Modalities
- Cell therapyEngineered cell therapiesEncapsulated cell therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Eli Lilly and Company (now parent company)
Beyond the preview
Go deeper on Sigilon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sigilon Therapeutics.